Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at Bentley University published a paper investigating the involvement of government…
Posts published in “Update”
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means fewer generic entrants and less opportunities for consumers to enjoy…
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th Portfolio Management & Pipeline Optimization for Generics from September 30th…
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is also increasing. Why might this…
Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s scientists, and some of the tools available. https://www.labmanager.com/ask-the-expert/trends-in-informatics-22895
Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights…
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and…
The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it is a matter of tracking…
Here’s a copy of the recent talk on Finding and Evaluating Branded and Generic Market Entry Opportunities. It’s based on the book Make Better Decisions, which distills insights gained from…
Considering switching to DrugPatentWatch? See why others have come to us. DrugPatentWatch Alternatives